Ensign Peak Advisors Inc Cuts Stock Position in West Pharmaceutical Services, Inc. (NYSE:WST)

Ensign Peak Advisors Inc decreased its holdings in shares of West Pharmaceutical Services, Inc. (NYSE:WST) by 29.2% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 164,745 shares of the medical instruments supplier’s stock after selling 68,023 shares during the quarter. Ensign Peak Advisors Inc owned about 0.23% of West Pharmaceutical Services worth $54,265,000 as of its most recent SEC filing.

Several other institutional investors have also bought and sold shares of the business. Pitcairn Co. raised its position in shares of West Pharmaceutical Services by 3.4% during the 1st quarter. Pitcairn Co. now owns 875 shares of the medical instruments supplier’s stock valued at $346,000 after buying an additional 29 shares in the last quarter. Copperwynd Financial LLC lifted its stake in shares of West Pharmaceutical Services by 4.0% in the 4th quarter. Copperwynd Financial LLC now owns 778 shares of the medical instruments supplier’s stock valued at $274,000 after purchasing an additional 30 shares during the last quarter. Clearbridge Investments LLC boosted its holdings in shares of West Pharmaceutical Services by 0.7% in the 1st quarter. Clearbridge Investments LLC now owns 4,495 shares of the medical instruments supplier’s stock worth $1,779,000 after purchasing an additional 31 shares during the period. RFG Advisory LLC increased its position in shares of West Pharmaceutical Services by 2.3% during the 1st quarter. RFG Advisory LLC now owns 1,465 shares of the medical instruments supplier’s stock valued at $580,000 after purchasing an additional 33 shares during the last quarter. Finally, Ballentine Partners LLC raised its holdings in West Pharmaceutical Services by 4.7% during the 2nd quarter. Ballentine Partners LLC now owns 742 shares of the medical instruments supplier’s stock valued at $244,000 after buying an additional 33 shares during the period. Institutional investors own 93.90% of the company’s stock.

West Pharmaceutical Services Stock Down 1.0 %

NYSE WST opened at $308.15 on Friday. The company has a quick ratio of 1.68, a current ratio of 2.34 and a debt-to-equity ratio of 0.03. West Pharmaceutical Services, Inc. has a 52 week low of $265.00 and a 52 week high of $413.70. The firm has a market capitalization of $22.45 billion, a price-to-earnings ratio of 40.65, a PEG ratio of 10.58 and a beta of 1.01. The company has a fifty day moving average of $303.37 and a two-hundred day moving average of $337.31.

West Pharmaceutical Services (NYSE:WST) last issued its quarterly earnings results on Thursday, July 25th. The medical instruments supplier reported $1.52 EPS for the quarter, missing the consensus estimate of $1.74 by ($0.22). The firm had revenue of $702.10 million for the quarter, compared to the consensus estimate of $729.36 million. West Pharmaceutical Services had a net margin of 18.25% and a return on equity of 19.17%. The business’s revenue for the quarter was down 6.9% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.11 earnings per share. On average, analysts predict that West Pharmaceutical Services, Inc. will post 6.42 earnings per share for the current year.

Insider Transactions at West Pharmaceutical Services

In related news, VP Charles Witherspoon sold 1,029 shares of the business’s stock in a transaction on Monday, August 19th. The stock was sold at an average price of $300.00, for a total transaction of $308,700.00. Following the completion of the transaction, the vice president now owns 1,478 shares in the company, valued at approximately $443,400. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 0.53% of the company’s stock.

West Pharmaceutical Services Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.